Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency

Laryngoscope

Volumn 125, Issue , 2015, Pages S1-S13

  Woodworth, Bradford A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

acquired CFTR deficiency; airway surface liquid; CFTR; chronic rhinosinusitis; cystic fibrosis; electrophysiology; hypoxia; ion transport; patch clamp; Resveratrol; sinusitis; Ussing chamber

Indexed keywords

CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; IVACAFTOR; RESVERATROL; CHLORIDE CHANNEL; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANION TRANSPORT; ARTICLE; CELL HYPOXIA; CHLORIDE CONDUCTANCE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ELECTROLYTE TRANSPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INSIDE OUT PATCH CLAMP; MOUSE; NONHUMAN; NOSE MUCOSA; NOSE SEPTUM; OPTICAL COHERENCE TOMOGRAPHY; PATCH CLAMP TECHNIQUE; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SECRETION (PROCESS); SHORT CIRCUIT CURRENT; SODIUM ABSORPTION; ACTIVE TRANSPORT; ANIMAL; ANOXIA; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; COMPLICATION; CONFOCAL MICROSCOPY; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; EPITHELIUM CELL; ION TRANSPORT; METABOLISM; MUCOCILIARY CLEARANCE; PARANASAL SINUS; PHOSPHORYLATION; PIG;

ANIMALS; ANOXIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; CHLORIDE CHANNELS; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; HEK293 CELLS; HUMANS; ION TRANSPORT; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; MUCOCILIARY CLEARANCE; NASAL MUCOSA; PARANASAL SINUSES; PATCH-CLAMP TECHNIQUES; PHOSPHORYLATION; STILBENES; SWINE;

EID: 84942191864     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.25335     Document Type: Article

References (64)

1. Bhattacharyya N,. Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol 2011; 120: 423-427.
2. Gliklich RE, Metson R,. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 1995; 113: 104-109.
3. Murphy MP, Fishman P, Short SO, Sullivan SD, Yueh B, Weymuller EA Jr,. Health care utilization and cost among adults with chronic rhinosinusitis enrolled in a health maintenance organization. Otolaryngol Head Neck Surg 2002; 127: 367-376.
4. Wanner A, Salathe M, O'Riordan TG,. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996; 154: 1868-1902.
5. Matsui H, Randell SH, Peretti SW, Davis CW, Boucher RC,. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998; 102: 1125-1131.
6. Trout L, King M, Feng W, Inglis SK, Ballard ST,. Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. Am J Physiol 1998; 274: L258-L263.
7. Phillips JE, Wong LB, Yeates DB,. Bidirectional transepithelial water transport: measurement and governing mechanisms. Biophys J 1999; 76: 869-877.
8. Knowles M, Gatzy J, Boucher R,. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest 1983; 71: 1410-1417.
9. Illing EA, Woodworth BA,. Management of the upper airway in cystic fibrosis. Curr Opin Pulm Med 2014; 20: 623-631.
10. Chaaban MR, Walsh EM, Woodworth BA,. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy 2013; 27: 473-478.
11. Chaaban MR, Kejner A, Rowe SM, Woodworth BA,. Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allergy 2013; 27: 387-395.
12. Virgin FW, Rowe SM, Wade MB, et al., Extensive surgical and comprehensive postoperative medical management for severe, recalcitrant cystic fibrosis chronic rhinosinusitis. Am J Rhinol Allergy 2012; 26: 70-75. doi: 10.2500/ajra.2012.26.3705.
13. Rowe SM, Miller S, Sorscher EJ,. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
14. Cobb BR, Ruiz F, King CM, et al., A(2) adenosine receptors regulate CFTR through PKA and PLA(2). Am J Physiol Lung Cell Mol Physiol 2002; 282: L12-L25.
15. Cohen NA, Zhang S, Sharp DB, et al., Cigarette smoke condensate inhibits transepithelial chloride transport and ciliary beat frequency. Laryngoscope 2009; 119: 2269-2274.
16. MacEachran DP, Stanton BA, O'Toole GA,. Cif is negatively regulated by the TetR family repressor CifR. Infect Immun 2008; 76: 3197-3206.
17. MacEachran DP, Ye S, Bomberger JM, et al., The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect Immun 2007; 75: 3902-3912.
18. Bebok Z, Varga K, Hicks JK, et al., Reactive oxygen nitrogen species decrease cystic fibrosis transmembrane conductance regulator expression and cAMP-mediated Cl- secretion in airway epithelia. J Biol Chem 2002; 277: 43041-43049.
19. Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H,. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol 2005; 288: L894-L902.
20. Sloane PA, Shastry S, Wilhelm A, et al., A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 2012; 7: e39809.
21. Cantin AM, Hanrahan JW, Bilodeau G, et al., Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006; 173: 1139-1144.
22. Bomberger JM, Ye S, Maceachran DP, et al., A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog 2011; 7: e1001325.
23. Alexander NS, Blount A, Zhang S, et al., Cystic fibrosis transmembrane conductance regulator modulation by the tobacco smoke toxin acrolein. Laryngoscope 2012; 122: 1193-1197.
24. Virgin FW, Azbell C, Schuster D, et al., Exposure to cigarette smoke condensate reduces calcium activated chloride channel transport in primary sinonasal epithelial cultures. Laryngoscope 2010; 120: 1465-1469.
25. Baroody FM,. Mucociliary transport in chronic rhinosinusitis. Clin Allergy Immunol 2007; 20: 103-119.
26. Pahl A, Szelenyi S, Brune K,. Hypoxia induced chemokine expression in nasal epithelial cells: development of an in vitro model for chronic rhinosinusitis. ALTEX 2006; 23: 59-63.
27. Steinke JW, Woodard CR, Borish L,. Role of hypoxia in inflammatory upper airway disease. Curr Opin Allergy Clin Immunol 2008; 8: 16-20.
28. Worlitzsch D, Tarran R, Ulrich M, et al., Effects of reduced mucus oxygen concentration in airway pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109: 317-325.
29. Aanaes K, Rickelt LF, Johansen HK, et al., Decreased mucosal oxygen tension in the maxillary sinuses in patients with cystic fibrosis. J Cyst Fibros 2011; 10: 114-120.
30. Accurso FJ, Rowe SM, Clancy JP, et al., Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
31. Van Goor F, Hadida S, Grootenhuis PD, et al., Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106: 18825-18830.
32. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, Kirk KL,. Regulation of plasma membrane recycling by CFTR. Science 1992; 256: 530-532.
33. Luo J, Zhu T, Evagelidis A, Pato MD, Hanrahan JW,. Role of protein phosphatases in the activation of CFTR (ABCC7) by genistein and bromotetramisole. Am J Physiol Cell Physiol 2000; 279: C108-C119.
34. Weinreich F, Wood PG, Riordan JR, Nagel G,. Direct action of genistein on CFTR. Pflugers Arch 1997; 434: 484-491.
35. Springsteel MF, Galietta LJ, Ma T, et al., Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 2003; 11: 4113-4120.
36. Galietta LJ, Springsteel MF, Eda M, et al., Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276: 19723-19728.
37. Caci E, Folli C, Zegarra-Moran O, et al., CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol 2003; 285: L180-L188.
38. Illek B, Lizarzaburu ME, Lee V, Nantz MH, Kurth MJ, Fischer H,. Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin. Am J Physiol Cell Physiol 2000; 279: C1838-1846.
39. Moran O, Galietta LJ, Zegarra-Moran O,. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 2005; 62: 446-460.
40. Melin P, Thoreau V, Norez C, Bilan F, Kitzis A, Becq F,. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem Pharmacol 2004; 67: 2187-2196.
41. Pyle LC, Ehrhardt A, Mitchell LH, et al., Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am J Physiol Lung Cell Mol Physiol 2011; 301: L587-L597.
42. Lee M, Kim S, Kwon OK, Oh SR, Lee HK, Ahn K,. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol 2009; 9: 418-424.
43. Donnelly LE, Newton R, Kennedy GE, et al., Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004; 287: L774-L783.
44. Manna SK, Mukhopadhyay A, Aggarwal BB,. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000; 164: 6509-6519.
45. Woodworth BA, Antunes MB, Bhargave G, et al., Murine nasal septa for respiratory epithelial air-liquid interface cultures. Biotechniques 2007; 43: 195-204.
46. Zhang S, Fortenberry JA, Cohen NA, Sorscher EJ, Woodworth BA,. Comparison of vectorial ion transport in primary murine airway and human sinonasal air-liquid interface cultures, models for studies of cystic fibrosis, and other airway diseases. Am J Rhinol Allergy 2009; 23: 149-152.
47. Woodworth BA, Tamashiro E, Bhargave G, Cohen NA, Palmer JN,. An in vitro model of Pseudomonas aeruginosa biofilms on viable airway epithelial cell monolayers. Am J Rhinol 2008; 22: 235-238.
48. Bhargave G, Woodworth BA, Xiong G, Wolfe SG, Antunes MB, Cohen NA,. Transient receptor potential vanilloid type 4 channel expression in chronic rhinosinusitis. Am J Rhinol 2008; 22: 7-12.
49. Woodworth BA, Antunes MB, Bhargave G, Palmer JN, Cohen NA,. Murine tracheal and nasal septal epithelium for air-liquid interface cultures: a comparative study. Am J Rhinol 2007; 21: 533-537.
50. Dean N, Ranganath NK, Jones B, et al., Porcine nasal epithelial cultures for studies of cystic fibrosis sinusitis. Int Forum Allergy Rhinol 2014; 4: 565-570.
51. Zhang S, Skinner D, Hicks SB, et al., Sinupret activates CFTR and TMEM16A-dependent transepithelial chloride transport and improves indicators of mucociliary clearance. PLoS One 2014; 9: e104090.
52. Lazrak A, Jurkuvenaite A, Ness EC, et al., Inter-alpha-inhibitor blocks epithelial sodium channel activation and decreases nasal potential differences in DeltaF508 mice. Am J Respir Cell Mol Biol 2014; 50: 953-962.
53. Solomon GM, Frederick C, Zhang S, et al., IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations. PLoS One 2013; 8: e72398.
54. Zhang S, Blount AC, McNicholas CM, et al., Resveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing cystic fibrosis transmembrane conductance regulator open probability. PLoS One 2013; 8: e81589.
55. Virgin F, Zhang S, Schuster D, et al., The bioflavonoid compound, sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope 2010; 120: 1051-1056.
56. Pyle LC, Fulton JC, Sloane PA, et al., Activation of CFTR by the flavonoid quercetin: potential use as a biomarker of {Delta}F508 CFTR rescue. Am J Respir Cell Mol Biol 2010; 43: 607-616. doi: 10.1165/rcmb.2009-0281OC.
57. Azbell C, Zhang S, Skinner D, Fortenberry J, Sorscher EJ, Woodworth BA,. Hesperidin stimulates cystic fibrosis transmembrane conductance regulator-mediated chloride secretion and ciliary beat frequency in sinonasal epithelium. Otolaryngol Head Neck Surg 2010; 143: 397-404.
58. Moran O, Zegarra-Moran O,. A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett 2005; 579: 3979-3983.
59. Accurso FJ, Rowe SM, Clancy JP, et al., Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
60. Khanna D, Sethi G, Ahn KS, et al., Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 2007; 7: 344-351.
61. Noone PG, Hamblett N, Accurso F, et al., Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol 2001; 32: 122-128.
62. Solomon GM, Konstan MW, Wilschanski M, et al., An international randomized multicenter comparison of nasal potential difference techniques. Chest 2010; 138: 919-928.
63. Blount A, Zhang S, Chestnut M, et al., Transepithelial ion transport is suppressed in hypoxic sinonasal epithelium. Laryngoscope 2011; 121: 1929-1934.
64. Alexander NS, Hatch N, Zhang S, et al., Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope 2011; 121: 1313-1319.